MCET (MultiCell Technologies) Cyclically Adjusted PS Ratio: (As of Sep. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MultiCell Technologies Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation

MultiCell Technologies  (OTCPK:MCET) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

MultiCell Technologies Cyclically Adjusted PS Ratio Related Terms

MultiCell Technologies Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies Cyclically Adjusted PS Ratio Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MCET vs ERGO, OPLI, GLAG: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, MultiCell Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MultiCell Technologies Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's Cyclically Adjusted PS Ratio falls into.


MultiCell Technologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

MultiCell Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Aug. 2015 is calculated as:

For example, MultiCell Technologies's adjusted Revenue per Share data for the three months ended in Aug. 2015 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Aug. 2015 (Change)*Current CPI (Aug. 2015)
=0/238.3160*238.3160
=0.000

Current CPI (Aug. 2015) = 238.3160.

MultiCell Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200511 0.002 197.600 0.002
200602 0.017 198.700 0.020
200605 0.001 202.500 0.001
200608 0.001 203.900 0.001
200611 0.002 201.500 0.002
200702 0.001 203.499 0.001
200705 0.001 207.949 0.001
200708 0.001 207.917 0.001
200711 0.002 210.177 0.002
200802 0.001 211.693 0.001
200805 0.001 216.632 0.001
200808 0.001 219.086 0.001
200811 0.001 212.425 0.001
200902 0.000 212.193 0.000
200905 0.000 213.856 0.000
200908 0.000 215.834 0.000
200911 0.000 216.330 0.000
201002 0.000 216.741 0.000
201005 0.000 218.178 0.000
201008 0.000 218.312 0.000
201011 0.000 218.803 0.000
201102 0.000 221.309 0.000
201105 0.000 225.964 0.000
201108 0.000 226.545 0.000
201111 0.000 226.230 0.000
201202 0.000 227.663 0.000
201205 0.000 229.815 0.000
201208 0.000 230.379 0.000
201211 0.000 230.221 0.000
201302 0.000 232.166 0.000
201305 0.000 232.945 0.000
201308 0.000 233.877 0.000
201311 0.000 233.069 0.000
201402 0.000 234.781 0.000
201405 0.000 237.900 0.000
201408 0.000 237.852 0.000
201411 0.000 236.151 0.000
201502 0.000 234.722 0.000
201505 0.000 237.805 0.000
201508 0.000 238.316 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.